236 related articles for article (PubMed ID: 36521904)
1. Biomarkers and outcomes in hospitalised patients with COVID-19: a prospective registry.
Khedar RS; Gupta R; Sharma K; Mittal K; Ambaliya HC; Gupta JB; Singh S; Sharma S; Singh Y; Mathur A
BMJ Open; 2022 Dec; 12(12):e067430. PubMed ID: 36521904
[TBL] [Abstract][Full Text] [Related]
2. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
4. Greater COVID-19 Severity and Mortality in Hospitalized Patients in the Delta-phase Compared to the Others: A Single Center Prospective Registry.
Khedar RS; Gupta R; Mittal K; Mathur A; Gupta JB; Singh Y; Sharma S; Sharma KK
J Assoc Physicians India; 2023 Jul; 71(7):11-12. PubMed ID: 37449685
[TBL] [Abstract][Full Text] [Related]
5. Low Vitamin D Status at Admission as a Risk Factor for Poor Survival in Hospitalized Patients With COVID-19: An Italian Retrospective Study.
Infante M; Buoso A; Pieri M; Lupisella S; Nuccetelli M; Bernardini S; Fabbri A; Iannetta M; Andreoni M; Colizzi V; Morello M
J Am Nutr Assoc; 2022; 41(3):250-265. PubMed ID: 33600292
[TBL] [Abstract][Full Text] [Related]
6. The study of serum hsCRP, ferritin, IL-6 and plasma D-dimer in COVID-19: a retrospective study.
Ahirwar AK; Takhelmayum R; Sakarde A; Rathod BD; Jha PK; Kumawat R; Gopal N
Horm Mol Biol Clin Investig; 2022 Sep; 43(3):337-344. PubMed ID: 35357792
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil to lymphocytic ratio and other inflammatory markers as adverse outcome predictor in hospitalized COVID-19 patients.
Abdelhady SA; Rageh F; Ahmed SS; Al-Touny SA; Riad E; Elhoseeny MM; Khalifa AA; Salim A; Farghly MI; Elgamal R
Egypt J Immunol; 2022 Apr; 29(2):57-67. PubMed ID: 35436055
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
[TBL] [Abstract][Full Text] [Related]
10. Impact of age to ferritin and neutrophil-lymphocyte ratio as biomarkers for intensive care requirement and mortality risk in COVID-19 patients in Makassar, Indonesia.
Rasyid H; Sangkereng A; Harjianti T; Soetjipto AS
Physiol Rep; 2021 May; 9(10):e14876. PubMed ID: 34042296
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis.
Malik P; Patel U; Mehta D; Patel N; Kelkar R; Akrmah M; Gabrilove JL; Sacks H
BMJ Evid Based Med; 2021 Jun; 26(3):107-108. PubMed ID: 32934000
[TBL] [Abstract][Full Text] [Related]
12. IL-6-based mortality risk model for hospitalized patients with COVID-19.
Laguna-Goya R; Utrero-Rico A; Talayero P; Lasa-Lazaro M; Ramirez-Fernandez A; Naranjo L; Segura-Tudela A; Cabrera-Marante O; Rodriguez de Frias E; Garcia-Garcia R; Fernández-Ruiz M; Aguado JM; Martinez-Lopez J; Lopez EA; Catalan M; Serrano A; Paz-Artal E
J Allergy Clin Immunol; 2020 Oct; 146(4):799-807.e9. PubMed ID: 32710975
[TBL] [Abstract][Full Text] [Related]
13. Retrospective Cohort Observational Study to compare the Effect of Mycobacterium w along with Standard of Care vs Standard of Care alone in critically ill COVID-19 Patients.
Dixit S; Zirpe K; Suryawanshi P; Borawake K; Prasad S; Ambapkar S; Ambapkar S; Joshi A; Joshi M
J Assoc Physicians India; 2022 Jul; 70(7):11-12. PubMed ID: 35833395
[TBL] [Abstract][Full Text] [Related]
14. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
Trials; 2021 May; 22(1):342. PubMed ID: 34001174
[TBL] [Abstract][Full Text] [Related]
15. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
[TBL] [Abstract][Full Text] [Related]
16. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 (IL-6) as a Predictor of Clinical Outcomes in Patients with COVID-19.
Mahmood SBZ; Majid H; Arshad A; Zaib-Un-Nisa ; Niazali N; Kazi K; Aslam A; Ahmed S; Jamil B; Jafri L
Clin Lab; 2023 Jun; 69(6):. PubMed ID: 37307132
[TBL] [Abstract][Full Text] [Related]
18. Utility of laboratory and immune biomarkers in predicting disease progression and mortality among patients with moderate to severe COVID-19 disease at a Philippine tertiary hospital.
Punzalan FER; Aherrera JAM; de Paz-Silava SLM; Mondragon AV; Malundo AFG; Tan JJE; Tantengco OAG; Quebral EPB; Uy MNAR; Lintao RCV; Dela Rosa JGL; Mercado MEP; Avenilla KC; Poblete JB; Albay AB; David-Wang AS; Alejandria MM
Front Immunol; 2023; 14():1123497. PubMed ID: 36926338
[TBL] [Abstract][Full Text] [Related]
19. The Evaluation of Laboratory Parameters as Predictors of Disease Severity and Mortality in COVID-19 Patients: A Retrospective Study From a Tertiary Care Hospital in India.
Dwivedi T; Raj A; Das N; Gupta R; Gupta N; Tiwari P; Sahoo B; Sagiraju HKR; Sirohiya P; Ratre B; Elavarasi A; Mohan A; Bhatnagar S
Cureus; 2023 Jun; 15(6):e40273. PubMed ID: 37448393
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of simple laboratory parameters in SARS-CoV-2 infection: the role of ratios.
Oblitas CM; Galeano-Valle F; Cuenca-Carvajal C; Piqueras-Ruiz S; Alonso-Beato R; Alejandre-de-Oña Á; Carrascosa-Fernández P; Chacón Moreno AD; Parra-Virto A; Pérez Sanz MT; Abarca Casas L; Millán-Nohales C; Álvarez-Sala-Walther L; Demelo-Rodríguez P
Infect Dis (Lond); 2022 Dec; 54(12):924-933. PubMed ID: 36221980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
